Cytoplasmic localization of 5hmC reveals RNA hydroxymethylation in breast cancer
This study reveals that breast cancer, particularly triple-negative and high-grade tumors, exhibits significant cytoplasmic RNA hydroxymethylation (5hmC) driven by TET3 upregulation, which correlates with altered RNA processing and spliceosomal gene expression.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of a preprint that has not been peer-reviewed. It is not medical advice. Do not make health decisions based on this content. Read full disclaimer
Inside every cell of the human body, a complex system of chemical tags acts as a control panel, deciding which genes are active and which are silent. One of the most important tags is a molecule called 5-methylcytosine, which generally acts as a "stop" sign, telling the cell to turn down the activity of specific genetic instructions. Scientists have long known that cancer cells often mess with these stop signs, leading to chaotic growth. In recent years, researchers discovered a related tag called 5-hydroxymethylcytosine. This molecule is created when the cell's machinery chemically modifies the original stop sign, effectively erasing it to allow genes to be read again. While this process is well understood in the cell's command center, the nucleus, scientists have largely ignored what happens in the rest of the cell, the cytoplasm, where the cell's daily work takes place. The question remained: does this chemical erasing happen outside the nucleus, and if so, does it affect the RNA molecules that carry instructions for building proteins?
A team of researchers at Imperial College London set out to answer this question by looking closely at breast cancer cells and tissue samples. They focused on a specific type of breast cancer known as triple-negative, which is often more aggressive and harder to treat because it lacks the receptors that many standard drugs target. The researchers used a specialized microscope technique to stain cells, allowing them to see where the chemical tags were located. They found that while the tags were indeed present in the nucleus, a significant amount was also floating in the cytoplasm. In fact, when they measured the total amount of these tags in the cell, nearly half of them were located in the cytoplasm, a finding that challenges the old view that these modifications only happen in the command center.
To be certain that these tags were attached to RNA and not just leftover DNA, the researchers performed a series of rigorous tests. They extracted RNA from the cells and treated some samples with an enzyme that destroys RNA but leaves DNA untouched. When the RNA was destroyed, the chemical signal vanished completely, proving that the tags were indeed sitting on the RNA molecules. They also confirmed that the signal was not a mistake caused by DNA contamination. This discovery revealed that breast cancer cells, particularly the aggressive triple-negative type, carry a high level of these chemical tags on their RNA, a feature that was previously unexplored in this disease.
The team then looked at human tissue samples from patients to see if this pattern held true in real people. They compared cancerous tissue to healthy tissue from the same patient. The results showed that while the healthy tissue had very few of these tags in the cytoplasm, the cancerous tissue was rich with them. The more aggressive the tumor, specifically those classified as grade 3 or triple-negative, the higher the concentration of these tags in the cytoplasm. This suggests that the presence of these tags in the cytoplasm is a distinct feature of the disease, not just a random occurrence.
The researchers then asked what was causing this buildup. They looked for the enzymes responsible for creating these tags, known as TET enzymes. They found that in the cancerous tissue, two specific enzymes, TET2 and TET3, were significantly more active in the cytoplasm than in the healthy tissue. To understand what these enzymes were doing, the team analyzed genetic data from hundreds of patients and found that when TET3 levels were high, the cells also showed high activity in genes responsible for processing RNA. Specifically, these genes were involved in the spliceosome, a molecular machine that edits RNA instructions before they are used to build proteins.
To test if TET3 was actually driving this process, the researchers reduced the amount of TET3 in breast cancer cells in the lab. When they did this, the levels of the RNA-processing genes dropped, confirming that TET3 plays a direct role in regulating these instructions. The study suggests that in aggressive breast cancers, TET3 moves into the cytoplasm and modifies RNA, potentially changing how the cell processes its genetic instructions. While the exact mechanism of how this modification changes the cell's behavior is still being investigated, the findings provide a new map of where these chemical changes occur. This work opens a new window into understanding how breast cancer cells rewire their internal machinery, offering a potential new angle for studying how these tumors grow and survive.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.